Search Results

Jul 24, 2026, 04:56 ET Shanghai Electric showcases embodied intelligence robot matrix and AI-native smart factory solutions at WAIC 2026

requirements.Shanghai Electric launched 51 AI models and agents under its "StarCloud Intelligent Manufacturing" series across three domains: R&D and design, production and manufacturing, and operations and maintenance—covering critical equipment processes such as process optimization and wind

More news about: Shanghai Electric

Jul 24, 2026, 04:20 ET Shanghai Electric showcases embodied intelligence robot matrix and AI-native smart factory solutions at WAIC 2026

requirements.Shanghai Electric launched 51 AI models and agents under its "StarCloud Intelligent Manufacturing" series across three domains: R&D and design, production and manufacturing, and operations and maintenance—covering critical equipment processes such as process optimization and wind

More news about: Shanghai Electric

Jul 24, 2026, 04:00 ET Beko Publishes 2025 Integrated Report, Charting Years of Progress Toward Net Zero

(based on volumes) and reached a consolidated turnover of 10.7 billion Euros in 2025. Beko's 28 R&D and Design Centers & Offices across the globe are home to over 2,000 R&D employees and hold more than 4,500 international registered patent applications to date. The company has

More news about: Beko

Jul 24, 2026, 04:00 ET Beko Publishes 2025 Integrated Report, Charting Years of Progress Toward Net Zero

(based on volumes) and reached a consolidated turnover of 10.7 billion Euros in 2025. Beko's 28 R&D and Design Centers & Offices across the globe are home to over 2,000 R&D employees and hold more than 4,500 international registered patent applications to date. The company has

More news about: Beko

Jul 24, 2026, 03:54 ET /C O R R E C T I O N -- MegazoneCloud/

More news about: MegazoneCloud

Jul 24, 2026, 01:06 ET InfiMotion Technology Tampil Perdana ke Publik, Pamerkan Kapabilitas Lengkap E-Drive di Wuxi

global. Kini, kami siap menjadi mitra tepercaya bagi industri otomotif yang lebih luas."Jaringan R&D Global yang Terhubung melalui Komputasi AwanInfiMotion memiliki jaringan R&D di Wuxi, Shanghai, Ningbo, Hangzhou, dan Gothenburg, yang didukung lebih dari 1.000 insinyur, termasuk

More news about: INFIMOTION

Jul 24, 2026, 00:44 ET Fractal posts 20% revenue growth and 92% net income growth in Q1 FY27

by embedding AI into critical decisions across business functions and industry verticals.Fractal invests more than 6% of its revenue in AI R&D, supporting foundational AI research, product development, and IP creation that address both immediate client needs and long-term technological advancement.

More news about: Fractal Analytics Limited

Jul 24, 2026, 00:38 ET Fractal posts 20% revenue growth and 92% net income growth in Q1 FY27

by embedding AI into critical decisions across business functions and industry verticals.Fractal invests more than 6% of its revenue in AI R&D, supporting foundational AI research, product development, and IP creation that address both immediate client needs and long-term technological advancement.

More news about: Fractal Analytics Limited

Jul 24, 2026, 00:26 ET Technological Breakthrough丨Niutech's Titanium-Iron Tailings Reduction and Enrichment Technology and Equipment Boost Global Strategic Mineral Resource Recovery

coordinated regulation, dynamic sealing, and smart control, enabling large-capacity continuous stable operation.Leveraging decades of R&D and engineering experience, Niutech partners with global mineral and solid waste customers to deliver cost-competitive, delivery-certain environmental

More news about: Niutech

Jul 24, 2026, 00:24 ET Fractal posts 20% revenue growth and 92% net income growth in Q1 FY27

by embedding AI into critical decisions across business functions and industry verticals.Fractal invests more than 6% of its revenue in AI R&D, supporting foundational AI research, product development, and IP creation that address both immediate client needs and long-term technological advancement.

More news about: Fractal Analytics Limited

Jul 23, 2026, 22:27 ET InfiMotion Technology chính thức ra mắt công chúng, giới thiệu năng lực phát triển toàn diện hệ thống truyền động điện tại sự kiện ở Vô Tích

cách là đối tác đáng tin cậy cho thị trường rộng lớn hơn".Mạng lưới R&D toàn cầu đồng bộ trên nền tảng đám mây: Kỹ thuật không biên giớiMạng lưới R&D của InfiMotion trải rộng tại Vô Tích, Thượng Hải, Ninh Ba, Hàng Châu và Gothenburg, với hơn 1.000

More news about: INFIMOTION

Jul 23, 2026, 21:30 ET Laminar Pharma Announces "Last Patient, Last Visit" in LAM561 Phase 2b/3 Trial for Newly Diagnosed Glioblastoma Patients

controls all processes, from the rational design of molecules to the clinical trials that lead to the launch of a new drug, with constant investment in R&D and high-quality standards. It is currently headquartered in Mallorca (Spain) with a subsidiary in Massachusetts (US).Forward-Looking Statements:

More news about: Laminar Pharmaceuticals, S.A.

Jul 23, 2026, 21:30 ET Laminar Pharma Announces "Last Patient, Last Visit" in LAM561 Phase 2b/3 Trial for Newly Diagnosed Glioblastoma Patients

controls all processes, from the rational design of molecules to the clinical trials that lead to the launch of a new drug, with constant investment in R&D and high-quality standards. It is currently headquartered in Mallorca (Spain) with a subsidiary in Massachusetts (US).Forward-Looking Statements:

More news about: Laminar Pharmaceuticals, S.A.

Jul 23, 2026, 21:00 ET ArkBio Completes all Cohort Dosing in Australian Phase I Trial with Influenza AFC Drug AK0406

therapeutics for respiratory/lung and pediatric diseases. Founded in 2014, the company has established proprietary technology platforms and a differentiated R&D pipeline through internal innovation and strategic collaborations.Key clinical pipeline assets include: ziresovir (AK0529), the first direct-acting

More news about: Shanghai Ark Biopharmaceutical Co., Ltd.

Jul 23, 2026, 21:00 ET ArkBio Completes all Cohort Dosing in Australian Phase I Trial with Influenza AFC Drug AK0406

therapeutics for respiratory/lung and pediatric diseases. Founded in 2014, the company has established proprietary technology platforms and a differentiated R&D pipeline through internal innovation and strategic collaborations.Key clinical pipeline assets include: ziresovir (AK0529), the first direct-acting

More news about: Shanghai Ark Biopharmaceutical Co., Ltd.

Jul 23, 2026, 20:02 ET Harbour BioMed Announces Positive Profit Alert for 2026 Interim Results, Marking Seventh Consecutive Profitable Half-Year as Platform-Based Advantages Drive Sustainable Growth

long-term commercial value.Looking ahead, supported by an expanding global partner network, a deeply integrated AI- and automation-enabled R&D platform, and a steadily advancing differentiated pipeline, Harbour BioMed is well positioned to continue delivering sustainable growth. With a strong

More news about: Harbour BioMed